These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 22614111

  • 1. Treatment with pamidronate for osteoporosis complicating long-term intestinal failure.
    Pastore S, Londero M, Barbieri F, Di Leo G, Paparazzo R, Ventura A.
    J Pediatr Gastroenterol Nutr; 2012 Nov; 55(5):615-8. PubMed ID: 22614111
    [Abstract] [Full Text] [Related]

  • 2. Osteoporosis in patients on long-term home parenteral nutrition: a longitudinal study.
    Cohen-Solal M, Baudoin C, Joly F, Vahedi K, D'Aoust L, De Vernejoul MC, Messing B.
    J Bone Miner Res; 2003 Nov; 18(11):1989-94. PubMed ID: 14606511
    [Abstract] [Full Text] [Related]

  • 3. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N, Ioannou YS, Kyriakou A, Savva SC, Efstathiou E, Savvides I, Christou S.
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P, Bruckner T, Hosch S, Haass M, Klar E, Sauer P, Ziegler R, Leidig-Bruckner G.
    Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
    [Abstract] [Full Text] [Related]

  • 6. Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits.
    Leung TF, Chu Y, Lee V, Cheng FW, Leung WK, Shing MM, Li CK.
    Hemoglobin; 2009 Jan; 33(5):361-9. PubMed ID: 19814683
    [Abstract] [Full Text] [Related]

  • 7. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.
    Walsh SB, Altmann P, Pattison J, Wilkie M, Yaqoob MM, Dudley C, Cockwell P, Sweny P, Banks LM, Hall-Craggs M, Noonan K, Andrews C, Cunningham J.
    Am J Kidney Dis; 2009 May; 53(5):856-65. PubMed ID: 19393473
    [Abstract] [Full Text] [Related]

  • 8. Metabolic bone disease in patients receiving home parenteral nutrition: a Canadian study and review.
    Raman M, Aghdassi E, Baun M, Yeung M, Fairholm L, Saqui O, Allard JP.
    JPEN J Parenter Enteral Nutr; 2006 May; 30(6):492-6. PubMed ID: 17047173
    [Abstract] [Full Text] [Related]

  • 9. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
    Monegal A, Guañabens N, Suárez MJ, Suárez F, Clemente G, García-González M, De la Mata M, Serrano T, Casafont F, Tome S, Barrios C, Navasa M.
    Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
    [Abstract] [Full Text] [Related]

  • 10. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C, Rauch F, Travers R, Glorieux FH.
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [Abstract] [Full Text] [Related]

  • 11. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP.
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [Abstract] [Full Text] [Related]

  • 12. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K, Aström E, Oscarsson KA, Söderhäll S, Eliasson AC.
    Acta Paediatr; 2007 Aug 30; 96(8):1180-3. PubMed ID: 17578486
    [Abstract] [Full Text] [Related]

  • 17. [Image assessment of the treatment effect on osteoporosis: bisphosphonates].
    Sone T.
    Clin Calcium; 2011 Jul 30; 21(7):1041-6. PubMed ID: 21719985
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC.
    J Bone Miner Res; 2005 Jun 30; 20(6):977-86. PubMed ID: 15883638
    [Abstract] [Full Text] [Related]

  • 20. Diagnosis and management of osteoporosis.
    Lash RW, Nicholson JM, Velez L, Van Harrison R, McCort J.
    Prim Care; 2009 Mar 30; 36(1):181-98, x. PubMed ID: 19231609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.